Leukotriene C4 production from human eosinophils in vitro. Role of eosinophil chemotactic factors on eosinophil activation.
We studied the role of naturally occurring eosinophil chemotactic factors on leukotriene (LT)C4 production from highly purified (87.1 +/- 2.4%) normodense eosinophils. Platelet activating factor (PAF) directly induced LTC4 production from eosinophils in a dose (10(-9) to 10(-5) M) and a time-dependent manner. PAF (10(-5) M) induced 0.74 +/- 0.08 ng of LTC4 production/10(6) eosinophils. However, lyso-PAF, eosinophil chemotactic factor of anaphylaxis, and LTB4 failed to induce LTC4 production within the tested range. Furthermore, the pre-incubation of eosinophils with 5 micrograms/ml of cytochalasin B did not alter the chemotactic factor-induced LTC4 production. When eosinophils were stimulated by the submaximal concentration (1 microgram/ml) of calcium ionophore A23187, the pre-incubation of eosinophils with 10(-6) M or 10(-5) M of PAF, or 10(-5) M of eosinophil chemotactic factor of anaphylaxis significantly enhanced LTC4 production up to 163.9 +/- 17.5% (p less than 0.05), 279.2 +/- 32.9% (p less than 0.01) and 165.2 +/- 21.2% (p less than 0.05) of the control, respectively. However, the pre-incubation with lyso-PAF or LTB4 failed to enhance A23187-induced LTC4 production. The pre-incubation of eosinophils with phosphatidyl serine also failed to enhance A23187-induced LTC4 production. However, the direct stimulation of protein kinase C by PMA enhanced the submaximal concentration of A23187-induced LTC4 production from eosinophils up to 179.5 +/- 20.9% (p less than 0.05) of the control. Our findings indicate that PAF and ECF-A work not only as chemotactic factors but also induce a functionally active state of eosinophils probably through their post-receptor mechanisms, and contribute to the inflammatory processes.
Tamura
N
N
Allergic Disease Center, Creighton University School of Medicine, Omaha, NE 68178.
Agrawal
D K
DK
Townley
R G
RG
D000328:Adult; D000001:Calcimycin; D002478:Cells, Cultured; D002630:Chemotactic Factors / Q000502:physiology*; D002631:Chemotactic Factors, Eosinophil / Q000502:physiology*; D004789:Enzyme Activation / Q000187:drug effects; D004804:Eosinophils / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D005260:Female; D006801:Humans; D007975:Leukotriene B4 / Q000502:physiology; D008297:Male; D010718:Phosphatidylserines / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000502:physiology; D011493:Protein Kinase C / Q000378:metabolism; D013189:SRS-A / Q000096:biosynthesis*; D013755:Tetradecanoylphorbol Acetate
D002630:Chemotactic Factors; D002631:Chemotactic Factors, Eosinophil; D010718:Phosphatidylserines; D010972:Platelet Activating Factor; D013189:SRS-A; D007975:Leukotriene B4; D000001:Calcimycin; D011493:Protein Kinase C; D013755:Tetradecanoylphorbol Acetate